Already offering the only non-invasive treatment for SMA in liquid form, Roche’s Evrysdi now comes as a tablet.

and Tysabri (natalizumab), as well as blockbuster spinal muscular atrophy therapy Spinraza (nusinersen). Biogen will retain its commercial rights to the biosimilars already brought to market ...

Biogen has invested heavily in its Alzheimer ... at a time when its big selling SMA drug Spinraza (nusinersen) is facing increased competitive pressure. At the same time, Sage has struggled ...

MRI imaging scans can track muscle changes in SMA children given Spinraza, a study found, with better results seen with early ...

The global Oligonucleotide Synthesis Market, valued at US$8.9 billion in 2024 stood at US$10.5 billion in 2025 and is projected to advance at ...

Real time quote data is not available at this time. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.